Navigation Links
OrbusNeich Files Lawsuit Against Dr. Pavel Cervinka for Defamation
Date:3/21/2011

jailed diagonal branch, which are recognized risk factors for stent thrombosis. It also revealed discrepancies in the reported data and inconsistencies and misrepresentations in the study and the reporting of the study. Upon presentation of the findings of the independent evaluation, Dr. Cervinka admitted that he had made mistakes; however, changes which he made to subsequent presentations and the publication of the study in a medical Journal did not correct the reporting of the defects in the study, nor admit nor publish the errors and invalidity of the study.

Dr. Cervinka presented the results and conclusions of the study a number of times after he and the Masaryk Hospital were made aware of the defects in the study and the study reporting. As a result of the wide dissemination of the study and its erroneous conclusions that were not supported by the data, numerous clinicians stopped using the product and terminated clinical trials, and OrbusNeich suffered reputational damage.  Despite many requests by OrbusNeich, neither Dr. Cervinka nor the Masaryk Hospital has made public disclosure of the defects or deficiencies in this invalid study.

Alfred J. Novak, Chairman and Chief Executive Officer of OrbusNeich, said, "OrbusNeich stents and its other products provide innovative therapies that improve the lives of patients around the world.  We have taken this action only after many unsuccessful attempts to try to work with Dr. Cervinka and the Masaryk Hospital to correct the record.  We informed Dr. Cervinka and the Masaryk Hospital about the inaccuracies, misrepresentations and inconsistencies that were unveiled by an independent reviewer of the study, and they acknowledged our position. Nevertheless Dr. Cervinka and Masaryk Hospital continued to widely present and publish the flawed and invalid study, resulting in damages to OrbusNeich's business and reputation.  While we attempted to resolve this issue amicably, the actions by Dr. C
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OrbusNeich Announces Availability of Azule™ Cobalt Chromium Stent
2. Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeichs Genous™ Stent
3. Safety and Efficacy of OrbusNeichs Genous™ Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy
4. OrbusNeich Granted Expanded U.S. Patent of Genous™ Endothelial Progenitor Cell Capture Technology
5. OrbusNeichs Genous™ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents
6. Randomized Clinical Trial of OrbusNeichs Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
7. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
8. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
9. OrbusNeichs Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease
10. 100 Percent Coverage of Struts and Complete Neointimal Coverage of OrbusNeichs Genous™ Bio-engineered R stent™ Demonstrated 26 Days Post-Implantation in STEMI Patient
11. Data Show OrbusNeichs Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  BC Technical, the largest nationwide, ... America , Inc., a leading provider of Siemens Nuclear ... long-term agreement naming BC Technical as the authorized provider ... MiE and BC Technical announced today that the ... BC Technical as the service and systems provider for ...
(Date:7/10/2014)... 2014 CVS Caremark Corporation (NYSE: CVS ... a quarterly dividend of $0.275 (27.5 cents) per share on ... 1, 2014, to holders of record on July 21, 2014. ... is dedicated to helping people on their path to better ... the United States . Through the company,s more than ...
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( ... "Dental Consumables Market - Global Industry Analysis, Size, Share, ... to their offering. (Logo: ... which are used on patients in order to treat ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... AMSTERDAM, May 31, 2011 Leading events organiser ... UBM), announced details of a new Logistics and Supply ... event dedicated to pharmaceutical contract services and outsourcing. ICSE ... Messe Frankfurt, Germany and is part of the world,s ...
... 2011 Volcano Corporation (NASDAQ: VOLC ), a ... guidance tools designed to enhance the treatment of coronary and ... in the Goldman Sachs 32nd Annual Global Healthcare Conference on ... 2:40 p.m., Pacific Daylight Time (5:40 p.m., Eastern Daylight Time). ...
Cached Medicine Technology:Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 2Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 3
(Date:7/14/2014)... Summer is the best season of the year for ... and other outdoor adventures. The promotional product experts at ... all summer long. The promo product gurus at 4AllPromos have ... imprinted products everyone must have on hand this summer. ... Sunscreen helps protect skin from harmful UV rays produced ...
(Date:7/14/2014)... Crystal Dental has recently announced that it ... been made via LAD Solutions in in order to increase ... made in order to draw in new patients that can ... Crystal Dental offers a variety of services for both routine ... Dental include cosmetic dentistry procedures such as porcelain veneers and ...
(Date:7/13/2014)... 14, 2014 FORT LEE, N.J. – Authors ... modern approach to the science of tooth implants ... This book describes recent advances and techniques in the ... that benefit people who have lost all of their natural ... the first lower subperiosteal implant in 1940. It was ...
(Date:7/13/2014)... Recently, TopDresses100.com, a popular dress company in ... multi-colored Quinceanera dresses to its product line. ... colorful outfits are guaranteed to be quality made. Now, ... off. , TopDresses100.com has a wide variety of elegant ... items are in stock and ready to ship. As ...
(Date:7/13/2014)... July 13, 2014 Manchester United and ... the 2014 Guinness International Champions Cup. The 2014 ICC ... each year because of the talent of it brings in. ... AS Roma will compete in the 2014 event spread across ... 24 with a game between Olympiacos and Milan and will ...
Breaking Medicine News(10 mins):Health News:Why These Three Summer Essentials from 4AllPromos Can Improve Summer 2Health News:Crystal Dental Announces the Opening of New Office Location in Sacramento 2Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 2Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 3Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 4Health News:Cheap Multi-colored Quinceanera Dresses From TopDresses100.com 2Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 2Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 3
... Established under the DOD Congressionally Directed Medical Research ... WASHINGTON, July 23 Today, Lung Cancer Alliance (LCA) announced ... is allotting approximately $1.2 million of the $20 million lung cancer ... , , (Logo: ...
... , , , ... , , SAN DIEGO, July 23 ... medical device company focused on developing products for minimally disruptive surgical treatments for the ... , NuVasive reported second quarter revenue of $88.5 million, a ...
... , , WASHINGTON, July ... elected John W. Bluford, president and CEO of Truman Medical Centers ... assume the chairmanship in 2011, becoming the top elected official of ... , , Bluford has been ...
... WASHINGTON, July 23 The Food and Drug Institute (FDLI) ... updated biographical information on recent Obama Administration appointees, including FDA Commissioner ... , The FDA Directory ... FDA personnel available, and contains listings of more than two dozen ...
... the epidemic might be slowing down among poor families ... preschoolers from low-income families in the United States are considered ... report finds that the news is not all bad: The ... children in this group. , Among 2- to 4-year-olds from ...
... , Woman spent remaining life in wheelchair, nursing facilities ... type , , KENT, Wash., July 23 ... Renton woman more than $1.8 million yesterday for a medical center,s ... routine back surgery. , , The ...
Cached Medicine News:Health News:Lung Cancer Alliance Announces First 'Request For Bids' for Department of Defense Lung Cancer Research Program 'Concept Awards' 2Health News:NuVasive Reports Second Quarter 2009 Financial Results 2Health News:NuVasive Reports Second Quarter 2009 Financial Results 3Health News:NuVasive Reports Second Quarter 2009 Financial Results 4Health News:NuVasive Reports Second Quarter 2009 Financial Results 5Health News:NuVasive Reports Second Quarter 2009 Financial Results 6Health News:NuVasive Reports Second Quarter 2009 Financial Results 7Health News:NuVasive Reports Second Quarter 2009 Financial Results 8Health News:NuVasive Reports Second Quarter 2009 Financial Results 9Health News:NuVasive Reports Second Quarter 2009 Financial Results 10Health News:NuVasive Reports Second Quarter 2009 Financial Results 11Health News:NuVasive Reports Second Quarter 2009 Financial Results 12Health News:AHA Board Elects John Bluford Chair-Elect Designate 2Health News:AHA Board Elects John Bluford Chair-Elect Designate 3Health News:1 in 7 Low-Income Preschoolers Is Obese 2Health News:Jury Awards Valley Medical Center Patient $1.8 Million for Nursing Negligence 2Health News:Jury Awards Valley Medical Center Patient $1.8 Million for Nursing Negligence 3
... The table-mounted knee ... exposure for total knee ... flexible, open-frame design allows ... the knee during the ...
... NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2) is a ... predicting acute renal failure with a >90% ... especially in urine, as early as 2 ... an ideal diagnostic marker for acute renal ...
... an assayed quality control material used for ... hemoglobin fractions on CO-Oximeter instrumentation. It provides ... that parallels the human physiologic range for ... available in three (3) levels for monitoring ...
... is an assayed quality control ... measurements of total hemoglobin and ... It is available in three ... performance at varying points within ...
Medicine Products: